Breaking News Instant updates and real-time market news.

NMTR

9 Meters Biopharma

$1.69 /

-0.04 (-2.31%)

08:50
11/29/22
11/29
08:50
11/29/22
08:50

9 Meters Biopharma announces Phase 3 study of vurolenatide

9 Meters Biopharma announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome. The study design follows the Company's successful End-of-Phase 2 meeting and incorporates input received from the U.S. Food and Drug Administration. The Phase 3 study, called VIBRANT 2, is a randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of vurolenatide 50 mg administered subcutaneously every two weeks for 12 weeks in adults with SBS. This international clinical study is designed to enroll approximately 105 patients with SBS and will be conducted in up to 50 clinical investigative sites in North America and Europe. The study population will include both SBS patients who meet the current parenteral support dependence definition and SBS patients who do not meet this PS requirement threshold. Patients with SBS suffer from severe malabsorption due to the lack of sufficient intestinal surface which results directly in severe and often debilitating fluid and nutritional losses in the form of chronic, recurrent diarrhea. This study will not only assess the degree to which vurolenatide can reduce weekly PS volume requirements, but it will also, for the first time in a large ambulatory study, assess the impact of vurolenatide on malabsorptive diarrhea as measured directly by total stool output volume. To maximize the potential for vurolenatide to provide clinical benefit to the entire SBS population regardless of PS requirement, VIBRANT 2 incorporates two primary efficacy endpoints: change from baseline in weekly PS volume which was the established primary efficacy outcome measure to support the approval of the GLP-2 agonist Gattex for treatment of SBS patients with a PS dependence; and change from baseline in mean 24-hour TSO volume, which assesses TSO volume over the entire treatment period and incorporates specific FDA recommendations around the inclusion of nutrition and hydration parameters to help establish the clinical relevance of this novel endpoint. Reduction in PS and TSO are both important clinical signs indicative of patients' ability to absorb nutrients and fluids. It is planned that success on either primary efficacy endpoint can be the basis for a potential future New Drug Application submission for vurolenatide. In addition, an interim analysis is planned specifically for the PS-dependent patient population. When 50% of patients with PS dependence reach week 12, the interim analysis will determine whether an additional 12 weeks which to date has been the regulatory predicate for GLP-2 agonists, will be required to assess safety and efficacy. All patients who complete the VIBRANT 2 double-blind treatment period will be eligible to enter an open-label extension study with the objective of assessing the long-term safety of vurolenatide for up to 12 months. U.S. Institutional Review Board approval has been secured, and study initiation is planned as early as the end of this year. Furthermore, several key features have been incorporated that we believe will optimize the ability to enroll the study, including utilizing a clinical research organization with specific experience executing late-stage clinical studies in SBS; securing up to 50 clinical study sites globally; and giving investigators the ability to enroll all SBS patients, regardless of PS status.

OTHER BREAKING NEWS FROM THE FLY

Recommendations
Take-Two price target raised to $130 from $120 at BMO Capital » 09:45
02/08/23
02/08
09:45
02/08/23
09:45
TTWO

Take-Two

$112.50 /

-1.33 (-1.17%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TTWO Take-Two
$112.50 /

-1.33 (-1.17%)

TTWO Take-Two
$112.50 /

-1.33 (-1.17%)

02/07/23 Roth MKM
Take-Two price target lowered to $130 from $140 at Roth MKM
02/07/23 Jefferies
Potential new gaming paradigm favors Take-Two in long run, says Jefferies
02/07/23 Benchmark
Take-Two price target lowered to $120 from $125 at Benchmark
02/07/23 Wedbush
Take-Two price target lowered to $130 from $140 at Wedbush
TTWO Take-Two
$112.50 /

-1.33 (-1.17%)

TTWO Take-Two
$112.50 /

-1.33 (-1.17%)

TTWO Take-Two
$112.50 /

-1.33 (-1.17%)

TTWO Take-Two
$112.50 /

-1.33 (-1.17%)

General news
NY Fed's Williams repeated that the Fed still has work to do on inflation » 09:45
02/08/23
02/08
09:45
02/08/23
09:45
$ECON

Economic Data

/

+

NY Fed's Williams…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Conference/Events
Cowen beverages/tobacco analyst to hold analyst/industry conference call » 09:45
02/08/23
02/08
09:45
02/08/23
09:45

Beverages, Tobacco &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Jefferies software/IT services analyst to hold analyst/industry conference call » 09:45
02/08/23
02/08
09:45
02/08/23
09:45
TMSNY

Temenos

$76.83 /

+5.63 (+7.91%)

Software & IT…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TMSNY Temenos
$76.83 /

+5.63 (+7.91%)

01/17/23 Credit Suisse
Temenos price target raised to CHF 51.50 from CHF 43 at Credit Suisse
01/17/23 JPMorgan
Temenos price target raised to CHF 79 from CHF 70 at JPMorgan
01/04/23 Morgan Stanley
Temenos price target lowered to CHF 70 from CHF 110 at Morgan Stanley
11/21/22 Barclays
Temenos price target raised to CHF 56 from CHF 52 at Barclays
Periodicals
GM competing for stake in Vale's base metals unit, Bloomberg reports » 09:44
02/08/23
02/08
09:44
02/08/23
09:44
GM

General Motors

$41.41 /

+ (+0.00%)

, VALE

Vale

$16.96 /

+ (+0.00%)

General Motors (GM) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GM General Motors
$41.41 /

+ (+0.00%)

VALE Vale
$16.96 /

+ (+0.00%)

GM General Motors
$41.41 /

+ (+0.00%)

02/02/23 Citi
Citi ups GM target, reiterates as top pick post results
02/01/23 Deutsche Bank
General Motors price target raised to $36 from $33 at Deutsche Bank
02/01/23 Morgan Stanley
General Motors price target raised to $35 from $32 at Morgan Stanley
02/01/23 BofA
General Motors price target lowered to $70 from $80 at BofA
VALE Vale
$16.96 /

+ (+0.00%)

02/06/23 RBC Capital
RBC downgrades Vale, says shares 'moved past fair value'
02/06/23 RBC Capital
Vale downgraded to Sector Perform from Outperform at RBC Capital
12/09/22 Morgan Stanley
Vale upgraded to Overweight from Equal Weight at Morgan Stanley
12/08/22 BMO Capital
Vale price target raised to $20 from $16 at BMO Capital
GM General Motors
$41.41 /

+ (+0.00%)

GM General Motors
$41.41 /

+ (+0.00%)

VALE Vale
$16.96 /

+ (+0.00%)

GM General Motors
$41.41 /

+ (+0.00%)

VALE Vale
$16.96 /

+ (+0.00%)

GM General Motors
$41.41 /

+ (+0.00%)

VALE Vale
$16.96 /

+ (+0.00%)

Options
Unusually active option classes on open February 8th » 09:40
02/08/23
02/08
09:40
02/08/23
09:40
UBER

Uber

$34.95 /

+0.04 (+0.11%)

, GOOGL

Alphabet

$107.69 /

-0.05 (-0.05%)

, CVS

CVS Health

$86.02 /

+ (+0.00%)

, GOOG

Alphabet

$108.01 /

+ (+0.00%)

, MSFT

Microsoft

$267.58 /

+ (+0.00%)

, BBAI

BigBear.ai

$4.94 /

+ (+0.00%)

, AI

C3.ai

$24.53 /

+ (+0.00%)

, BIDU

Baidu

$160.21 /

+ (+0.00%)

, LQD

iShares iBoxx $ Investment Grade Corporate Bond

$109.34 /

+ (+0.00%)

, ATVI

Activision Blizzard

$75.61 /

+ (+0.00%)

Unusual total active…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$109.34 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

01/31/23 Mizuho
Mizuho 'constructive' on Uber shares into Q4 results
01/30/23 MoffettNathanson
Uber initiated with an Outperform at MoffettNathanson
01/26/23 Cowen
Uber price target lowered to $66 from $70 at Cowen
01/24/23 KeyBanc
KeyBanc upgrades Lyft on 'meaningful opportunity' for EBITDA lift
GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

08:20 Today DA Davidson
Microsoft price target raised to $325 from $280 at DA Davidson
07:53 Today Loop Capital
Alphabet price target raised to $125 from $120 at Loop Capital
02/07/23 Wedbush
Microsoft set to unveil ChatGPT partnership as AI arms race begins, says Wedbush
02/03/23 Truist
Alphabet price target lowered to $120 from $130 at Truist
CVS CVS Health
$86.02 /

+ (+0.00%)

08:07 Today Piper Sandler
Oak Street Health downgraded to Neutral from Overweight at Piper Sandler
07:36 Today Stifel
Oak Street Health downgraded to Hold from Buy at Stifel
02/07/23 Stifel
Oak Street Health price target raised to $39 from $35 at Stifel
02/07/23 Piper Sandler
Oak Street 'particularly attractive' in current environment, says Piper Sandler
GOOG Alphabet
$108.01 /

+ (+0.00%)

02/07/23 Wedbush
Microsoft set to unveil ChatGPT partnership as AI arms race begins, says Wedbush
02/03/23 JPMorgan
Alphabet price target raised to $118 from $115 at JPMorgan
02/03/23 Credit Suisse
Alphabet price target lowered to $136 from $145 at Credit Suisse
02/03/23 Morgan Stanley
Alphabet price target raised to $135 from $125 at Morgan Stanley
MSFT Microsoft
$267.58 /

+ (+0.00%)

08:38 Today Morgan Stanley
Microsoft 'coming out swinging' in ramping AI/ML tech cycle, says Morgan Stanley
08:20 Today DA Davidson
Microsoft price target raised to $325 from $280 at DA Davidson
07:31 Today Wells Fargo
Wells says OpenAI investments place Microsoft 'front & center' of AI hype cycle
06:42 Today Mizuho
Microsoft price target raised to $300 from $280 at Mizuho
BBAI BigBear.ai
$4.94 /

+ (+0.00%)

08/10/22 Oppenheimer
Oppenheimer downgrades BigBear.ai to Perform following 'disappointing' quarter
08/10/22 Oppenheimer
BigBear.ai downgraded to Perform from Outperform at Oppenheimer
03/28/22 Oppenheimer
BigBear.ai initiated with an Outperform at Oppenheimer
02/09/22 William Blair
BigBear.ai initiated with a Market Perform at William Blair
AI C3.ai
$24.53 /

+ (+0.00%)

02/02/23 DA Davidson
C3.ai initiated with a Buy at DA Davidson
12/08/22 Morgan Stanley
C3.ai price target lowered to $12 from $13 at Morgan Stanley
12/08/22 Piper Sandler
C3.ai price target lowered to $13 from $14 at Piper Sandler
12/08/22 Deutsche Bank
C3.ai price target lowered to $11 from $13 at Deutsche Bank
BIDU Baidu
$160.21 /

+ (+0.00%)

01/31/23 Citi
Baidu price target raised to $176 from $166 at Citi
01/20/23 UBS
Baidu price target lowered to $182 from $185 at UBS
01/17/23 Jefferies
Baidu price target lowered to $210 from $217 at Jefferies
12/14/22 Susquehanna
Baidu price target lowered to $150 from $195 at Susquehanna
LQD iShares iBoxx $ Investment Grade Corporate Bond
$109.34 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

01/27/23 Wedbush
Activision Blizzard assumed with an Outperform at Wedbush
12/22/22 Needham
Netflix 2023 estimates cut at Needham
12/06/22 Edward Jones
Activision Blizzard upgraded to Buy from Hold at Edward Jones
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$109.34 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

Recommendations
Model N price target raised to $48 from $42 at BTIG » 09:36
02/08/23
02/08
09:36
02/08/23
09:36
MODN

Model N

$40.82 /

+0.555 (+1.38%)

BTIG analyst Matt…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MODN Model N
$40.82 /

+0.555 (+1.38%)

MODN Model N
$40.82 /

+0.555 (+1.38%)

09:06 Today Truist
Model N price target raised to $52 from $45 at Truist
11/09/22 Needham
Model N price target raised to $42 from $34 at Needham
11/09/22 Truist
Model N price target raised to $45 from $35 at Truist
11/09/22 Craig-Hallum
Model N price target raised to $42 from $34 at Craig-Hallum
MODN Model N
$40.82 /

+0.555 (+1.38%)

MODN Model N
$40.82 /

+0.555 (+1.38%)

Recommendations
TransDigm price target raised to $810 from $710 at Truist » 09:34
02/08/23
02/08
09:34
02/08/23
09:34
TDG

TransDigm

$742.31 /

+21.96 (+3.05%)

Truist analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TDG TransDigm
$742.31 /

+21.96 (+3.05%)

TDG TransDigm
$742.31 /

+21.96 (+3.05%)

08:55 Today RBC Capital
TransDigm price target raised to $800 from $750 at RBC Capital
07:43 Today Credit Suisse
TransDigm price target raised to $830 from $765 at Credit Suisse
07:35 Today Cowen
TransDigm price target raised to $830 from $695 at Cowen
07:28 Today Susquehanna
TransDigm price target raised to $750 from $665 at Susquehanna
TDG TransDigm
$742.31 /

+21.96 (+3.05%)

Hot Stocks
Titan Medical to resume trading at 9:50 am ET » 09:34
02/08/23
02/08
09:34
02/08/23
09:34
TMDI

Titan Medical

/

+

Shares of Titan Medical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TMDI Titan Medical
/

+

TMDI Titan Medical
/

+

03/25/22 Oppenheimer
Titan Medical downgraded to Perform from Outperform at Oppenheimer
03/25/22 Oppenheimer
Titan Medical downgraded to Perform from Outperform at Oppenheimer
TMDI Titan Medical
/

+

Periodicals
General Motors competing for stake in Vale base metals unit, Bloomberg says » 09:31
02/08/23
02/08
09:31
02/08/23
09:31
GM

General Motors

$41.41 /

+0.075 (+0.18%)

, VALE

Vale

$16.96 /

-0.01 (-0.06%)

General Motors (GM) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GM General Motors
$41.41 /

+0.075 (+0.18%)

VALE Vale
$16.96 /

-0.01 (-0.06%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

02/02/23 Citi
Citi ups GM target, reiterates as top pick post results
02/01/23 Deutsche Bank
General Motors price target raised to $36 from $33 at Deutsche Bank
02/01/23 Morgan Stanley
General Motors price target raised to $35 from $32 at Morgan Stanley
02/01/23 BofA
General Motors price target lowered to $70 from $80 at BofA
VALE Vale
$16.96 /

-0.01 (-0.06%)

02/06/23 RBC Capital
RBC downgrades Vale, says shares 'moved past fair value'
02/06/23 RBC Capital
Vale downgraded to Sector Perform from Outperform at RBC Capital
12/09/22 Morgan Stanley
Vale upgraded to Overweight from Equal Weight at Morgan Stanley
12/08/22 BMO Capital
Vale price target raised to $20 from $16 at BMO Capital
GM General Motors
$41.41 /

+0.075 (+0.18%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

VALE Vale
$16.96 /

-0.01 (-0.06%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

VALE Vale
$16.96 /

-0.01 (-0.06%)

Recommendations
Malibu Boats price target raised to $72 from $65 at Truist » 09:30
02/08/23
02/08
09:30
02/08/23
09:30
MBUU

Malibu Boats

$63.43 /

+0.85 (+1.36%)

Truist analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MBUU Malibu Boats
$63.43 /

+0.85 (+1.36%)

11/07/22 Raymond James
Malibu Boats price target lowered to $75 from $88 at Raymond James
11/07/22 BMO Capital
Malibu Boats price target lowered to $76 from $94 at BMO Capital
10/25/22 B. Riley
Malibu Boats price target lowered to $74 from $89 at B. Riley
10/05/22 Truist
Malibu Boats price target lowered to $65 from $75 at Truist
MBUU Malibu Boats
$63.43 /

+0.85 (+1.36%)

Recommendations
Fiserv price target raised to $105 from $95 at Truist » 09:27
02/08/23
02/08
09:27
02/08/23
09:27
FISV

Fiserv

$115.29 /

+8.86 (+8.32%)

Truist analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FISV Fiserv
$115.29 /

+8.86 (+8.32%)

FISV Fiserv
$115.29 /

+8.86 (+8.32%)

08:34 Today Credit Suisse
Fiserv price target raised to $130 from $115 at Credit Suisse
07:35 Today RBC Capital
Fiserv price target raised to $131 from $123 at RBC Capital
07:28 Today Morgan Stanley
Fiserv price target raised to $117 from $107 at Morgan Stanley
07:24 Today Susquehanna
Fiserv price target raised to $140 from $135 at Susquehanna
FISV Fiserv
$115.29 /

+8.86 (+8.32%)

FISV Fiserv
$115.29 /

+8.86 (+8.32%)

FISV Fiserv
$115.29 /

+8.86 (+8.32%)

Hot Stocks
1847 Cabinets intends to file registration statement for IPO » 09:26
02/08/23
02/08
09:26
02/08/23
09:26
EFSH

1847 Holdings

$1.88 /

-0.03 (-1.57%)

1847 Cabinets announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EFSH 1847 Holdings
$1.88 /

-0.03 (-1.57%)

EFSH 1847 Holdings
$1.88 /

-0.03 (-1.57%)

Hot Stocks
374Water, Inc. to conduct field demonstration of AirSCWO system » 09:26
02/08/23
02/08
09:26
02/08/23
09:26
SCWO

374Water, Inc.

$3.22 /

-0.18 (-5.29%)

374Water has partnered…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
    Recommendations
    Aecom price target raised to $102 from $94 at RBC Capital » 09:25
    02/08/23
    02/08
    09:25
    02/08/23
    09:25
    ACM

    Aecom

    $90.63 /

    +2.24 (+2.53%)

    RBC Capital analyst…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    02/07/23 Baird
    Aecom price target raised to $103 from $90 at Baird
    01/17/23 KeyBanc
    Aecom price target raised to $100 from $91 at KeyBanc
    01/13/23 Barclays
    Aecom price target raised to $94 from $90 at Barclays
    01/12/23 Credit Suisse
    Aecom upgraded to Outperform from Neutral at Credit Suisse
    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    Hot Stocks
    Dori Segal says majority of First Capital REIT board should be replaced » 09:24
    02/08/23
    02/08
    09:24
    02/08/23
    09:24
    FCXXF

    First Capital REIT

    $13.12 /

    -0.1263 (-0.95%)

    Dori Segal, whose family…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    FCXXF First Capital REIT
    $13.12 /

    -0.1263 (-0.95%)

    01/30/23 National Bank
    First Capital REIT price target raised to C$18.50 from C$17 at National Bank
    11/03/22 Canaccord
    First Capital REIT price target raised to C$18.50 from C$17.50 at Canaccord
    11/03/22 Scotiabank
    First Capital REIT price target lowered to C$19 from C$19.50 at Scotiabank
    09/19/22 Industrial Alliance
    First Capital REIT initiated with a Buy at Industrial Alliance
    Recommendations
    New Relic price target raised to $65 from $55 at Truist » 09:22
    02/08/23
    02/08
    09:22
    02/08/23
    09:22
    NEWR

    New Relic

    $64.61 /

    +1.21 (+1.91%)

    Truist analyst Joel…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    07:58 Today RBC Capital
    New Relic price target raised to $75 from $55 at RBC Capital
    07:42 Today Credit Suisse
    New Relic price target raised to $90 from $78 at Credit Suisse
    07:39 Today Wedbush
    New Relic price target raised to $75 from $68 at Wedbush
    07:33 Today Morgan Stanley
    New Relic price target raised to $80 from $67 at Morgan Stanley
    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    Hot Stocks
    Cassava Sciences provides enrollment update for Phase 3 studies of simufilam » 09:21
    02/08/23
    02/08
    09:21
    02/08/23
    09:21
    SAVA

    Cassava Sciences

    $29.83 /

    +0.23 (+0.78%)

    Cassava Sciences…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    01/25/23 B. Riley
    Cassava Sciences price target lowered to $28 from $44 at B. Riley
    01/24/23 H.C. Wainwright
    H.C. Wainwright positive on Cassava data, says buy the selloff
    11/29/22 Univest Securities
    Cassava Sciences price target lowered to $11 from $12 at Univest Securities
    11/16/22 B. Riley
    Cassava Sciences downgraded to Neutral at B. Riley amid limited disclosures
    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    Hot Stocks
    Titan Medical trading halted, news pending  09:20
    02/08/23
    02/08
    09:20
    02/08/23
    09:20
    TMDI

    Titan Medical

    /

    +

     
    ShowHide Related Items >><<
    TMDI Titan Medical
    /

    +

    TMDI Titan Medical
    /

    +

    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    TMDI Titan Medical
    /

    +

    Hot Stocks
    Humana and ChenMed announce five-year network agreement » 09:20
    02/08/23
    02/08
    09:20
    02/08/23
    09:20
    HUM

    Humana

    $481.12 /

    -5.085 (-1.05%)

    ChenMed, a senior-focused…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    02/07/23 Truist
    Humana price target lowered to $560 from $580 at Truist
    02/06/23 Cowen
    Humana price target lowered to $581 from $647 at Cowen
    02/06/23 Credit Suisse
    Humana price target lowered to $575 from $635 at Credit Suisse
    02/03/23 Stephens
    Humana price target lowered to $590 from $625 at Stephens
    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    Recommendations
    Lake Street sees opportunity in 'muted' reaction to S&W Seed pact with Shell » 09:20
    02/08/23
    02/08
    09:20
    02/08/23
    09:20
    SANW

    S&W Seed

    $1.70 /

    +0.16 (+10.39%)

    , SHEL

    Shell

    $59.61 /

    +1.77 (+3.06%)

    Lake Street analyst Ben…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    SANW S&W Seed
    $1.70 /

    +0.16 (+10.39%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SANW S&W Seed
    $1.70 /

    +0.16 (+10.39%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    01/23/23 Morgan Stanley
    Shell downgraded to Equal Weight from Overweight at Morgan Stanley
    01/18/23 Redburn
    Shell downgraded to Neutral from Buy at Redburn
    01/12/23 Wolfe Research
    Shell downgraded to Peer Perform from Outperform at Wolfe Research
    12/19/22 Piper Sandler
    Shell price target lowered to $70 from $71 at Piper Sandler
    SANW S&W Seed
    $1.70 /

    +0.16 (+10.39%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    Hot Stocks
    Titan Medical to prioritize sale of company's assets, layoff 48 employees » 09:19
    02/08/23
    02/08
    09:19
    02/08/23
    09:19
    TMDI

    Titan Medical

    /

    +

    Titan Medical provided an…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    TMDI Titan Medical
    /

    +

    TMDI Titan Medical
    /

    +

    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    TMDI Titan Medical
    /

    +

    Recommendations
    BP price target raised to 650 GBp from 550 GBp at RBC Capital » 09:18
    02/08/23
    02/08
    09:18
    02/08/23
    09:18
    BP

    BP

    $37.73 /

    +2.91 (+8.36%)

    RBC Capital analyst Biraj…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    06:25 Today Bernstein
    BP price target raised to $53 from $48 at Bernstein
    02/07/23 TD Securities
    BP upgraded to Buy from Hold at TD Securities
    01/23/23 Morgan Stanley
    BP price target raised to 636 GBp from 603 GBp at Morgan Stanley
    01/19/23 JPMorgan
    BP price target lowered to 540 GBp from 560 GBp at JPMorgan
    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    Recommendations
    Inspire Medical price target raised to $305 from $250 at Lake Street » 09:17
    02/08/23
    02/08
    09:17
    02/08/23
    09:17
    INSP

    Inspire Medical

    $249.33 /

    +5.91 (+2.43%)

    Lake Street analyst Frank…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    07:45 Today Truist
    Inspire Medical price target raised to $330 from $310 at Truist
    04:30 Today Piper Sandler
    Inspire Medical price target raised to $305 from $300 at Piper Sandler
    01/31/23 Truist
    Inspire Medical price target raised to $310 from $308 at Truist
    01/31/23 Lake Street
    CVRx initiated with a Buy at Lake Street
    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    • 12
      Aug
    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    Hot Stocks
    Avantax appoints Melissa Loner as CCO » 09:16
    02/08/23
    02/08
    09:16
    02/08/23
    09:16
    AVTA

    Avantax

    $29.20 /

    +0.365 (+1.27%)

    Avantax announced the…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    AVTA Avantax
    $29.20 /

    +0.365 (+1.27%)

    AVTA Avantax
    $29.20 /

    +0.365 (+1.27%)

    Get Full Fly Access

    Breaking market intelligence sent straight to you
    Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
    Up-to-date information on important industry events
    Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
    News focused on the companies in your portfolio
    Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.